Mesoblast (MESO) Cash from Investing Activities (2014 - 2023)
Mesoblast (MESO) posted Cash from Investing Activities of $16000.0 for Q2 2023, down 40.74% sequentially from $27000.0 in Q1 2023, and up 134.04% YoY from $6836.4 in Q2 2022.
Powered by 
Analysis
Mesoblast (MESO) Cash from Investing Activities (2014 - 2023) Analysis & Trends
Mesoblast has reported Cash from Investing Activities for 8 years, with the latest figure at $16000.0 in Q2 2023.
- Quarterly Cash from Investing Activities rose 134.04% year-over-year to $16000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$194000.0 (up 16.38% YoY) and the FY2025 annual result came in at $120000.0, up 223.71% from the prior year.
- Cash from Investing Activities retreated to $16000.0 in Q2 2023 per MESO's latest filing, from $27000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $27000.0 in Q1 2023 and troughed at -$1.9 million in Q2 2020.
- A 5-year average of -$346333.3 and a median of -$151000.0 in 2021 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2020 and 2023: Cash from Investing Activities slumped 670.0% in 2020, then surged 148.21% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$459000.0 in 2019, then gained by 11.33% to -$407000.0 in 2020, then soared by 92.63% to -$30000.0 in 2021, then declined by 13.33% to -$34000.0 in 2022, then jumped by 147.06% to $16000.0 in 2023.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $16000.0, $27000.0, and -$34000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 16,000.00 |
| Mar 31, 2023 | 27,000.00 |
| Dec 31, 2022 | -34,000.00 |
| Sep 30, 2022 | -203,000.00 |
| Jun 30, 2022 | -47,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Sep 30, 2021 | -99,000.00 |
| Jun 30, 2021 | -223,000.00 |
| Mar 31, 2021 | -936,000.00 |
| Dec 31, 2020 | -407,000.00 |
| Sep 30, 2020 | -81,000.00 |
| Mar 31, 2020 | -1.41 Mn |
| Dec 31, 2019 | -712,000.00 |
| Sep 30, 2019 | -253,000.00 |
| Mar 31, 2019 | -90,000.00 |
| Dec 31, 2018 | 141,000.00 |
| Sep 30, 2018 | -39,000.00 |
| Jun 30, 2018 | -436,000.00 |
| Mar 31, 2018 | -37,000.00 |